Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804384 | 0.74 | CTSS (0.41) | ITGB3ITGB1ITGAVITGA5CTSS | |
| SCHEMBL7181514 | 0.73 | RAB9A (0.50) | ITGB3ITGB1ITGAVITGA5NPC1 | |
| SCHEMBL9087858 | 0.73 | RAB9A (0.50) | ITGB3ITGB1ITGAVITGA5NPC1 | |
| SCHEMBL6799563 | 0.73 | KMT2A (0.48) | CTSSNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6802479 | 0.72 | CTSS (0.43) | CTSSACHEBACE1NPC1RAB9A | |
| SCHEMBL6807685 | 0.71 | NPC1 (0.41) | ITGB3ITGB1ITGAVITGA5NPC1 | |
| SCHEMBL6802803 | 0.70 | CTSS (0.41) | ITGB3ITGB1ITGAVITGA5CTSS | |
| SCHEMBL6802536 | 0.68 | NPC1 (0.41) | ITGB3ITGB1ITGAVITGA5ACHE | |
| SCHEMBL3862351 | 0.64 | HRH3 (0.72) | ACHEBACE1NPC1RAB9ABCHE | |
| SCHEMBL23023176 | 0.64 | EPHX2 (0.50) | ITGB3ITGB1ITGAVITGA5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | ITGB3 4232/4885ITGB1 4140/4885ITGAV 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.